Effect of induction therapy on Hepatitis C

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Chronic hepatitis C is a significant global health concern.
• Standard treatment regimens have varying efficacy rates.
• Understanding optimal therapeutic strategies is crucial for patient outcomes.

Purpose of the Study:

• To evaluate the effectiveness of a one-month induction combination therapy using alpha interferon and Ribavirin.
• To compare this induction therapy with a standard 12-month regimen.
• To assess sustained virologic and biochemical responses in patients with chronic hepatitis C.

Main Methods:

• Eighty treatment-naive patients with chronic hepatitis C received a one-month induction of alpha interferon and Ribavirin, followed by 11 months of standard therapy.
• Twenty-seven patients received the standard 12-month regimen.
• Response was assessed by viral load and liver enzymes.

Main Results:

• The induction therapy group showed higher rates of end-of-treatment response (48.7% vs. 40.7%), sustained virologic response (36.2% vs. 18.5%), and sustained biochemical response (46.2% vs. 22.2%).
• Patients with cirrhosis did not achieve sustained virologic response in either group.
• Sustained virologic response was higher in patients with genotype-one and 4 in the induction group (31.4% vs. 15.3%).

Conclusions:

• One-month induction combination therapy with alpha interferon and Ribavirin enhances sustained biochemical and virologic responses.
• This approach may prevent early viral mutations, contributing to a lower relapse rate.
• Induction therapy represents a promising strategy for managing chronic hepatitis C.